Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 601–700 of 1,000
Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4
Quezada, S. A., & Peggs, K. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2509 · Cited by 46
Self-citationImmune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Duitman, J., van den Ende, T., & Spek, C. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101547 · Cited by 48
“Moreover, the expression of CTLA-4 on Tregs also leads to the depletion of these cells in the TIME after administration of an anti-CTLA-4 agent serving another mechanism explaining the therapeutic efficacy of CTLA-4 check point inhibitors [44,45].”
BackgroundAbnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy
Deng, K., Yao, J., Huang, J., Ding, Y., & Zuo, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101077 · Cited by 47
John, P., Pulanco, M. C., Galbo, P. M., Yao, W., Ohaegbulam, K. C., Zheng, D., & Zang, X. (2022) · Nature Communications · doi:10.1038/s41467-022-30143-8 · Cited by 49
Aptamers: novelty tools for cancer biology
Pereira, R. L., Nascimento, I. C., Santos, A. P. D. J., Ogusuku, I. E. Y., Lameu, C., Mayer, G., & Ulrich, H. (2018) · Oncotarget · doi:10.18632/oncotarget.25260 · Cited by 52
Toffoli, E. C., Sheikhi, A., Höppner, Y. D., de Kok, P., Yazdanpanah‐Samani, M., Spanholtz, J., Verheul, H. M. W., van der Vliet, H. J., & de Gruijl, T. D. (2021) · Cancers · doi:10.3390/cancers13040711 · Cited by 47
STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets
Bhatt, D., Kang, B., Sawant, D., Zheng, L., Perez, K., Huang, Z., Sekirov, L., Wolak, D., Huang, J. Y., Liu, X., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201329 · Cited by 45
“Owing to previous publications demonstrating that the CT26 tumor model is sensitive to anti–CTLA-4 monotherapy (Selby et al., 2013; Simpson et al., 2013), we decided to first evaluate the antitumor potential of targeting CCR8 as a single agent in the CT26 tumor model.”
BackgroundMethodHarris, K. E., Lorentsen, K. J., Malik-Chaudhry, H. K., Loughlin, K., Basappa, H. M., Hartstein, S., Ahmil, G., Allen, N. S., Avanzino, B. C., Balasubramani, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90096-8 · Cited by 45
Mason, N. J., Chester, N., Xiong, A., Rotolo, A., Wu, Y., Yoshimoto, S., Glassman, P. M., Gulendran, G., & Siegel, D. L. (2021) · mAbs · doi:10.1080/19420862.2021.2004638 · Cited by 49
Cancer immunotherapy in clinical practice��the past, present, and future
Goel, G., & Sun, W. (2014) · 癌症:英文版 · doi:10.5732/cjc.014.10123 · Cited by 53
“The inhibition of CTLA-4 results in the reactivation and proliferation of T cells([22]) and also decreases the number of suppressive Treg cells in tumor tissues([56]), thereby shifting the tumor microenvironment from immunosuppressive to inflammatory([57]).”
BackgroundImmunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
“This in turn has been shown to enhance Tcell activation, increase neoantigen-specific CD8 T cells in the tumor microenvironment, and deplete immunosuppressive T regulatory cells [52, 53].”
BackgroundAge effects of distinct immune checkpoint blockade treatments in a mouse melanoma model
Padrón, Á., Hurez, V., Gupta, H. B., Clark, C. A., Pandeswara, S. L., Yuan, B., Svatek, R. S., Turk, M. J., Drerup, J. M., Li, R., et al. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.025 · Cited by 44
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
Yamazaki, T., Wennerberg, E., Hensler, M., Buqué, A., Kraynak, J., Fucikova, J. P., Zhou, X. K., Sveinbjørnsson, B., Rekdal, Ø., Demaria, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1962592 · Cited by 44
“TREG cells were decreased in TS/ A tumors exposed to CTLA4 blockers (Figure 1e and S3A), as expected.(27) A significant reduction of PD-1CD8 T cells coupled to an accumulation of TIM-3CD4 T cells was seen in both primary and abscopal TS/A lesions from the RT + CTLA4 blockage treatment arm (Figure 1e and S3A, B).”
ResultThe tumor immune-microenvironment in gastric cancer
Fang, F., Zhang, T., Li, Q., Chen, X., Jiang, F., & Shen, X. (2022) · Tumori Journal · doi:10.1177/03008916211070051 · Cited by 47
Su, P., Li, O., Ke, K., Jiang, Z., Wu, J., Wang, Y., Mou, Y., & Jin, W. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5648 · Cited by 47
“Of note, TAMs express the ligands of CTLA‑4 and play an important role in T cell‑mediated immune response (242).”
BackgroundShapiro, R. M., Sheffer, M., Booker, M. A., Tolstorukov, M. Y., Birch, G. C., Sade-Feldman, M., Fang, J., Li, S., Lu, W. S., Ansuinelli, M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01669-3 · Cited by 46
“MS is funded by the Sidney Farber Scholar Program, Dana Farber, and RR is a recipient of the Career Development Award from the Leukemia and Lymphoma Society and is a member of the Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute.”
FcγR requirements leading to successful immunotherapy
Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015) · Immunological Reviews · doi:10.1111/imr.12342 · Cited by 45
Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo
Hock, K., Laengle, J., Kuznetsova, I., Egorov, A., Hegedűs, B., Döme, B., Wekerle, T., Sachet, M., & Bergmann, M. M. (2016) · Surgery · doi:10.1016/j.surg.2016.08.045 · Cited by 45
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity
Bakhru, P., Zhu, M., Wang, H., Hong, L. K., Khan, I. S., Mouchess, M. L., Gulati, A., Starmer, J., Hou, Y., Sailer, D., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93265 · Cited by 45
“aCTLA-4 antibody treatment has been reported to have pleiotropic effects on T cells, which include intratumoral Treg depletion and promoting increased Teff/Treg ratios (18, 22, 38, 39).”
BackgroundResultPhenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
Lee, G. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/5458178 · Cited by 52
“The effect of ipilimumab was recently substantiated by depleting Treg cells via antibody-dependent cell-mediated cytotoxicity (ADCC) [89].”
BackgroundTumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Shklovskaya, E., Lee, J., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P. M., Saw, R. P. M., Thompson, J. F., Shivalingam, B., Carlino, M. S., et al. (2020) · Cancers · doi:10.3390/cancers12113374 · Cited by 49
“Although the development of such cells has been documented in animal models and linked to regulatory T-cell depletion by anti-CTLA-4 [25], there is no indication that this mechanism also operates in humans [26].”
BackgroundBringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 45
“macrophages synergize with anti-CTLA-4 immunotherapy [55] as well as actively participate in tumor cell clearance with tumor-specific mAb [56].”
BackgroundTreg cell IL-10 and IL-35 exhaust CD8+ T cells in tumors
Damo, M., & Joshi, N. S. (2019) · Nature Immunology · doi:10.1038/s41590-019-0389-y · Cited by 46
Cancer Immunotherapy: Whence and Whither
Stambrook, P. J., Maher, J. F., & Farzaneh, F. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0427 · Cited by 46
“For example, a subpopulation of regulatory CD4þ T cells (Tregs) can effectively interfere with the function of APCs (98, 99).”
BackgroundInfluentialMaaß, F., Wüstehube‐Lausch, J., Dickgießer, S., Valldorf, B., Reinwarth, M., Schmoldt, H., Daneschdar, M., Avrutina, O., Şahin, U., & Kolmar, H. (2015) · Journal of Peptide Science · doi:10.1002/psc.2782 · Cited by 44
Xue, W., Metheringham, R. L., Brentville, V. A., Gunn, B., Symonds, P., Yagita∥, H., Ramage, J. M., & Durrant, L. G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1169353 · Cited by 43
“the presence of Fcg receptor-expressing receptor macrophage.(50) This is consistent with our results in which antiCTLA-4 and anti-PD-1 Abs failed to increase the immune response to SCIB2 but did enhance its antitumor response with 100% of mice showing long-term survival with the SCIB2/antiPD-1 combination.”
BackgroundResultSelf-citationSundahl, N., Wolf, K. D., Krüse, V., Meireson, A., Reynders, D., Goetghebeur, E. J. T., Gele, M. V., Speeckaert, R., Hennart, B., Brochez, L., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.11.029 · Cited by 43
Common gamma chain cytokines and CD8 T cells in cancer
Shourian, M., Beltra, J., Bourdin, B., & Decaluwe, H. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101307 · Cited by 47
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
“This promotes antitumor response through expansion of tumor-infiltrating T cells and possibly the depletion of regulatory T-cell (Treg) populations, which are immunosuppressive and downregulate the activation and proliferation of effector T cells [9].”
BackgroundMuth, S. T., Saung, M. T., Blair, A. B., Henderson, M., Thomas, D. L., & Zheng, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.041 · Cited by 43
“This CTLA4 antibody was shown to deplete Tregs expressing CTLA4 in the TME [31].”
BackgroundFcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis
Petrelli, F., Ferrara, R., Signorelli, D., Ghidini, A., Proto, C., Roudi, R., Sabet, M. N., Facelli, S., Garassino, M. C., Luciani, A., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0224 · Cited by 42
Majedi, F. S., Hasani‐Sadrabadi, M. M., Thauland, T. J., Keswani, S. G., Li, S., Bouchard, L., & Butte, M. J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00977-0 · Cited by 42
Frijlink, E., Bosma, D. M. T., Busselaar, J., Battaglia, T., Staal, M. D., Verbrugge, I., & Borst, J. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171154 · Cited by 46
“To evaluate the effects of CTLA-4 blockade in our lymphocyte-depleted TC-1 tumor model, we treated tumors with RT and either vehicle or a blocking antibody against CTLA-4 that does not deplete Tregs (52, 53) on successive days.”
Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition
Wang, Y., Sparwasser, T. D., Figlin, R. A., & Kim, H. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2928 · Cited by 42
CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Ren, Z., Guo, J., Liao, J., Luan, Y., Liu, Z., Sun, Z., Liu, X., Liang, Y., Peng, H., & Fu, Y.-X. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0040 · Cited by 42
“CTLA-4 is important for the suppressive function of Tregs in tumor evasion (33-38).”
BackgroundRole of Fc–FcγR interactions in the antitumor activity of therapeutic antibodies
Barnhart, B. C., & Quigley, M. M. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.121 · Cited by 45
Zhang, L., Zhang, M., Jin-xiu, X., Li, S., Chen, Y., Wang, W., Yang, J., Li, S., & Gu, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6719 · Cited by 43
Sharma, N., Fan, X., Atolagbe, O. T., Ge, Z., Dao, K., Sharma, P., & Allison, J. P. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231263 · Cited by 43
“Lastly, macrophages can contribute to the depletion of Tregs bound by CTLA-4 antibodies, further enhancing antitumor immunity (Selby et al., 2013; Sharma et al., 2019; Simpson et al., 2013).”
BackgroundSelf-citationFrampton, S., Smith, R., Ferson, L., Gibson, J., Hollox, E. J., Cragg, M. S., & Strefford, J. C. (2024) · Immunological Reviews · doi:10.1111/imr.13401 · Cited by 47
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
Alme, A., Karir, B. S., Faltas, B. M., & Drake, C. G. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.01.006 · Cited by 45
“The therapeutic effects of CTLA-4 blockade seem to be due primarily to enhancing the effector function of T cells [11], though more recent data suggest that antiCTLA-4 antibodies may function by depleting regulatory T cell (Treg) as well [12,13].”
BackgroundAmplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
Melosky, B. L., Juergens, R. A., Hirsh, V., McLeod, D., Leighl, N. B., Tsao, M., Card, P. B., & Chu, Q. S.-C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0027 · Cited by 43
Goldberg, A. D., Atallah, E. L., Rizzieri, D. A., Walter, R. B., Chung, K.-Y., Spira, A. I., Stock, W., Tallman, M. S., Cruz, H. G., Boni, J. P., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106385 · Cited by 41
Gleisner, M. A., Pereda, C., Tittarelli, A., Navarrete, M., Fuentes, C., Ávalos, I., Tempio, F., Araya, J. P., Becker, M. I., González, F. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000999 · Cited by 42
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
“In line with this, an on-treatment increase in intratumoral Teff:Treg ratio conditions optimal immune control of the tumor under anti-CTLA-4 in a number of models [77, 78, 80, 85].”
BackgroundImplications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
Dwivedi, M., Tiwari, S., Kemp, E. H., & Begum, R. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10450 · Cited by 42
Antibody-based cancer immunotherapy by targeting regulatory T cells
Li, Q., Lu, J., Li, J., Zhang, B., Wu, Y., & Ying, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1157345 · Cited by 47
Berrien-Elliott, M. M., Yuan, J., Swier, L. E., Jackson, S. R., Chen, C. L., Donlin, M. J., & Teague, R. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0159 · Cited by 42
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Li, Y., Liu, J., Gao, L., Liu, Y., Meng, F., Li, X., & Qin, F. X.-F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.006 · Cited by 44
Han, J., Cai, M., Grein, J., Perera, S. A., Wang, H., Bigler, M., Ueda, R., Rosahl, T. W., Pinheiro, E. M., LaFace, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573405 · Cited by 40
“Anti-TIGIT:mIgG2a Antibodies Do Not Deplete Intratumoral Tregs It has been established in several mouse tumor models that an anti-CTLA-4 antibody on the mIgG2a isotype induces antitumor responses via depletion of intratumoral regulatory T cells via FcγRIV engagement (14).”
BackgroundResultBiology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
Motofei, I. G. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.003 · Cited by 43
Hanson, A., Elpek, K., Duong, E., Shallberg, L., Fan, M., Johnson, C., Wallace, M., Mabry, G. R., Sazinsky, S., Pepper, L., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239595 · Cited by 39
“This effect is similar to what was described regarding Treg depletion after anti-CTLA-4 treatment which was shown to be mediated by FcgRIV expressed on myeloid cells in tumors [29].”
ResultSelf-citationFc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
Anastasiou, P., Moore, C., Rana, S., Tomaschko, M., Pillsbury, C. E., de Castro, A., Boumelha, J., Mugarza, E., Trécesson, S. D. C., Mikolajczak, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52324-3 · Cited by 42
Gálvez‐Cancino, F., Navarrete, M., Beattie, G., Puccio, S., Conde, E., Foster, K. A., Morris, Y., Sahwangarrom, T., Karagianni, D., Liu, J., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.021 · Cited by 43
Self-citationImmunotherapy for breast cancer: past, present, and future
Spellman, A., & Tang, S.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9654-9 · Cited by 43
“Not only does ipilimumab result in an increase ratio of effector T cells/T-regs, but recent studies have demonstrated ADCC against intratumoral T-regs [15, 16].”
BackgroundChecks and Balances in Autoimmune Vasculitis
Cadena, R. H., Abdulahad, W. H., Hospers, G. A. P., Wind, T. T., Boots, A. M. H., Heeringa, P., & Brouwer, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00315 · Cited by 43
Importance of the immune system in head and neck cancer
Mirza, A. H., Thomas, G. J., Ottensmeier, C. H. H., & King, E. V. (2019) · Head & Neck · doi:10.1002/hed.25716 · Cited by 44
“There is also evidence to suggest that anti CTLA-4 monoclonal antibodies cause regulatory T-cell depletion in the tumor microenvironment.(49,50) To date, a clear predictive biomarker for benefit from CTLA-4 blockade has not emerged, although it is likely that patients with TIL-rich tumors are likely to benefit, especi…”
BackgroundKwon, S., Velasquez, F. C., Rasmussen, J. C., Greives, M. R., Turner, K. D., Morrow, J. R., Hwu, W., Ross, R. F., Zhang, S., & Sevick-Muraca, E. M. (2019) · Theranostics · doi:10.7150/thno.35280 · Cited by 41
“While anti-CTLA-4 has also been shown to modify the immune status of the tumor microenvironment [1], the intrinsic site of therapeutic action for anti-CTLA-4 in locally advanced metastatic cancers remains in the tumor draining LNs (TDLNs) where naïve T-cells are activated against tumor Ags.”
BackgroundTargeting T Cell Activation in Immuno-Oncology
Saibil, S. D., & Ohashi, P. S. (2020) · Current Oncology · doi:10.3747/co.27.5285 · Cited by 42
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 45
“Upon anti-CTLA-4 mAb treatment, the ratio of Teffs to Tregs was positively associated with treatment response, which is dependent on the presence of Fcγ receptor-expressing macrophages [58,59], suggesting the use of anti-CTLA4 antibodies with enhanced FcγR binding profiles to achieve robust anti-tumor responses and im…”
BackgroundKnorr, D. A., Blanchard, L., Leidner, R. S., Jensen, S. M., Meng, R., Jones, A., Ballesteros‐Merino, C., Bell, R. B., Baez, M., Marino, A. E., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0389 · Cited by 41
“Tregs express A large proportion of the research aiming at establishing whether human anti – CTLA-4 deplete Tregs in vivo has relied on mouse models (5 – 11).”
Self-citationImmune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 40
“Thus, anti-CTLA-4 antibody may indirectly interfere with the immunosuppressive functions of regulatory T cells, or it may directly deplete them from the tumor microenvironment (TME) by targeting them for Fc receptor–mediated clearance (Simpson et al. 2013).”
BackgroundChung, C. K., Silva, C. G. D., Kralisch, D., Chan, A. B., OSSENDORP, F. A., & Cruz, L. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.011 · Cited by 40
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 41
Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
Lin, R. A., Lin, J. K., & Lin, S. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12375 · Cited by 40
“seen in mice undergoing anti-CTLA4 therapy, contributing to antitumor efficacy.(102) Findings show that ipilimumab therapy additionally leads to TCR repertoire broadening,(103) as the absence of the TCR-signal-attenuating CTLA4 means that effective T-cell activation thresh-”
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
“This effect was convincingly shown in mice, where anti-CTLA-4 antibody caused strong depletion of Tregs from the tumor [64].”
BackgroundImmune Effector Functions of Human IgG2 Antibodies against EGFR
Rösner, T., Kahle, S., Montenegro, F., Matlung, H. L., Jansen, J. H. M., Evers, M., Beurskens, F. J. M., Leusen, J. H. W., van den Berg, T. K., & Valerius, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0341 · Cited by 42
PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis
Pereira, J. A., Lanzar, Z. R., Clark, J. T., Hart, A. P., Douglas, B. B., Shallberg, L. A., O’Dea, K. M., Christian, D. A., & Hunter, C. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.997376 · Cited by 40
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 39
“The anti-tumor effects of CTLA-4 blockade have been shown to be accompanied by an increase in effector T cells and a decrease in Tregs, thereby leading to an elevated ratio of intratumoral effector T cells to Tregs in mouse tumor models (15, 16).”
BackgroundTargeting macrophages: a novel avenue for cancer drug discovery
Kumar, S., Ramesh, A., & Kulkarni, A. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733525 · Cited by 37
“total depletion of this population is not ideal for immune checkpoint inhibitor combination therapies [47,48].”
BackgroundThe two-faces of NK cells in oncolytic virotherapy
Marotel, M., Hasim, M. S., Hagerman, A., & Ardolino, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.005 · Cited by 37
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Amon, L., Hatscher, L., Heger, L., Dudziak, D., & Lehmann, C. H. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070663 · Cited by 40
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Facchinetti, F., Marabelle, A., Rossi, G., Soria, J., Besse, B., & Tiseo, M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.027 · Cited by 43
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Spasevska, I., Sharma, A., Steen, C. B., Josefsson, S. E., Blaker, Y. N., Kolstad, A., Rustad, E. H., Meyer, S., Isaksen, K. T., Chellappa, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010158 · Cited by 38
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coaña, Y. P., Masucci, G. V., Hansson, J., & Kiessling, R. W. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1570-7 · Cited by 39
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
Subhash, V. V., Yeo, M. S., Tan, W. L., & Yong, W. P. (2015) · Journal of Immunology Research · doi:10.1155/2015/308574 · Cited by 43
“Observations made to date suggest that anti-CTLA-4 antibodies functionnot only by blocking inhibitory signals from reaching effector T cells but also by depleting the T reg cells present in the tumor microenvironment [93].”
BackgroundWhiteside, S. K., Grant, F. M., Alvisi, G., Clarke, J. D., Tang, L., Imianowski, C. J., Zhang, B., Evans, A. C., Wesolowski, A. J., Conti, A. G., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo5558 · Cited by 39
Checkpoint blockade in combination with cancer vaccines
Morse, M. A., & Lyerly, H. K. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.057 · Cited by 35
Induced Expression of FcγRIIIa (CD16a) on CD4+ T Cells Triggers Generation of IFN-γhigh Subset
Chauhan, A., Chen, C., Moore, T. L., & DiPaolo, R. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599266 · Cited by 36
“A role for activating Fc- receptors in therapies targeting T cell antigen such as CTLA-4 and GITR is suggested (58, 59).”
BackgroundNa, Y. R., Kwon, J. W., Kim, D.-Y., Chung, H., Song, J., Jung, D., Quan, H., Kim, D., Kim, J., Ju, Y. W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107643 · Cited by 36
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 38
Semmrich, M., Marchand, J.-B., Fend, L., Rehn, M., Remy, C., Holmkvist, P., Silvestre, N., Svensson, C., Kleinpeter, P., Deforges, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003488 · Cited by 37
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 42
“CTLA-4 signalling plays an important role in the immunosuppressive function of T-regs, and as such, blockade of such signalling removes this immunosuppressive influence that otherwise promotes tumour growth and progression [42].”
BackgroundControl of Regulatory T Cells by Co-signal Molecules
Wing, J. B., Tay, C., & Sakaguchi, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_7 · Cited by 37
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Sheikholeslami, S. A., Salari, S., & Bashash, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103160 · Cited by 35
Alternol triggers immunogenic cell death via reactive oxygen species generation
Li, C., Zhang, Y., Yan, S., Zhang, G., Wei, W., Qi, Z., & Li, B. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1952539 · Cited by 35
Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application
Miyashita, M., Shimizu, T., Ashihara, E., & Ukimura, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168910 · Cited by 36
Zhang, H., Feng, L., Mello, P. D. A., Mao, C., Near, R. I., Csizmadia, E., Chan, L. L., Enjyoji, K., Gao, W., Zhao, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157431 · Cited by 35
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Xu, W., Zhang, W., Zhao, D., Wang, Q., Zhang, M., Li, Q., Zhu, W., & Xu, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242909 · Cited by 36
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances
Greppi, M., Franco, F. D., Obino, V., Rebaudi, F., Goda, R., Frumento, D., Vita, G., Baronti, C., Melaiu, O., Bozzo, M., et al. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106932 · Cited by 34
Oh, D. S., Kim, H., Oh, J. E., Jung, H. E., Lee, Y. S., Park, J., & Lee, H. K. (2017) · Oncotarget · doi:10.18632/oncotarget.17663 · Cited by 33
Pereira, M. B., Barros, L. R. C., Bracco, P. A., Vigo, Á., Boroni, M., Bonamino, M., & Lenz, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431083 · Cited by 37
Single-Cell Proteomics for Cancer Immunotherapy
Li, L., Yan, S., Lin, B., Shi, Q., & Lu, Y. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.006 · Cited by 34
Dorta-Estremera, S. M., Chin, R. L., Sierra, G., Nicholas, C., Yanamandra, A. V., Nookala, S. M. K., Yang, G., Singh, S., Curran, M. A., & Sastry, K. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0892 · Cited by 33
“In accordance with this, we observed that the treatment comprised of HPV vaccination along with α4-1BB or αCD40 antibodies significantly reduced the intratumoral frequency of Tregs (CD4 + FoxP3 + ) compared to treatment with either antibody alone (Fig.”
InfluentialNK Cell-Fc Receptors Advance Tumor Immunotherapy
Sanseviero, E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101667 · Cited by 34
“In the tumor microenvironment, myeloid cells, monocytes, macrophages, neutrophils, and NK cells comprise the two main subsets of Fc-receptor expressing cells [23,34,35,37,40].”
BackgroundGreiner, J., Götz, M., Bunjes, D. W., Hofmann, S., & Wais, V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010039 · Cited by 35
“Thus, the reduction of Treg could improve the efficacy of other immunotherapies or immune checkpoint inhibitors [20].”
BackgroundKines, R. C., Thompson, C. D., Spring, S. M., Li, Z., Pinos, E. D. L., Monks, S. A., & Schiller, J. T. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0974 · Cited by 33
“There is precedence for T-reg depletion with anti-CTLA-4 therapy thought to be Fc-mediated clearance (46), and because B cells also express CTLA-4, it is plausible that they too are”
Background
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.